Inhibition of endocannabinoid metabolism attenuates enhanced hippocampal neuronal activity induced by kainic acid

Synapse

Volumn 62, Issue 10, 2008, Pages 746-755

  Coomber, B ^a,c   O'Donoghue, Michael F ^b   Mason, Robert ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cannabinoid; CB1; Electrophysiology; FAAH; Hippocampus; Multi electrode; Rat; URB597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; ISOFLURANE; KAINIC ACID; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; HIPPOCAMPUS; MALE; METABOLISM; MICROELECTRODE; NERVE CELL; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZAMIDES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; HIPPOCAMPUS; KAINIC ACID; MALE; NEURAL INHIBITION; NEURONS; PIPERIDINES; PYRAZOLES; RATS;

EID: 50249101147     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20547     Document Type: Article

References (52)

1. Alexander SPH, Kendall DA. 2007. The complications of promiscuity: Endocannabinoid action and metabolism. Br J Pharmacol 152:602-623.
2. Ben-Ari Y. 1985. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14:375-403.
3. Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ. 2006. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther 317:1072-1078.
4. Buckmaster PS, Dudek FE. 1997a. Network properties of the dentate gyrus in epileptic rats with hilar neuron loss and granule cell axon reorganization. J Neurophysiol 77:2685-2696.
5. Buckmaster PS, Dudek FE. 1997b. Neuron loss, granule cell axon reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated rats. J Comp Neurol 385:385-404.
6. Buckmaster PS, Dudek FE. 1999. In vivo intracellular analysis of granule cell axon reorganization in epileptic rats. J Neurophysiol 81:712-721.
7. Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M, Dinh TP, Piomelli D, Mackie K, Soltesz I. 2003. Long-term plasticity of endocannabinoid signalling induced by developmental febrile seizures. Neuron 39:599-611.
8. Chen K, Neu A, Howard AL, Foldy C, Echegoyen J, Hilgenberg L, Smith M, Mackie K, Soltesz I. 2007. Prevention of plasticity of endocannabinoid signalling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci 27:46-58.
9. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. 2003. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23:3916-3923.
10. Cravatt BF, Lichtman AH. 2003. Fatty acid amide hydrolase: An emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475.
11. Cravatt BP, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
12. Deutsch DG, Chin SA. 1993. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796.
13. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Zieglgansberger W, Lutz B, Rammes G. 2006. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26:5794-5799.
14. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. 2005. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358.
15. Frank LM, Brown EN, Wilson MA. 2001. A comparison of the firing properties of putative excitatory and inhibitory neurons from CA1 and the entorhinal cortex. J Neurophysiol 86:2029-2040.
16. Freund TF, Katona I, Piomelli D. 2003. Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 83:1017-1066.
17. Gardiner SM, March JE, Kemp PA, Bennett T. 2002. Influence of the CB(1) receptor antagonist. AM251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136:581-587.
18. Hájos N, Freund TF. 2002. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503-510.
19. Hájos N, Ledent C, Freund TF. 2001. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4.
20. Hauser WA, Kurland LT. 1975. The epidemiology of epilepsy in Rochester. Minnesota, 1935 through 1967. Epilepsia 16:1-66.
21. Hauser WA, Annegers JF, Kurland LT. 1991. Prevalence of epilepsy in Rochester. Minnesota: 1940-1980. Epilepsia 32:429-445.
22. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1991. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
23. Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB. 1995. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1257:249-256.
24. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB. 1997. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69:631-638.
25. Hong LJ, Mubarak WA, Sunami Y, Murakami S, Fuyama Y, Ohtsuka A, Murakami T. 2000. Enhanced visualization of weak colloidal iron signals with Bodian's protein silver for demonstration of perineuronal nets of proteoglycans in the central nervous system. Arch Histol Cytol 63:459-465.
26. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
27. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. 2006. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288.
28. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF. 1999. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
29. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
30. Kunz T, Oliw EH. 2001. Nimesulide aggravates kainic acid-induced seizures in the rat. Pharmacol Toxicol 88:271-276.
31. Lothman EW, Collins RC, Ferrendelli JA. 1981. Kainic acid-induced limbic seizures: Electrophysiologic studies. Neurology 31:806-812.
32. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A. 2000. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 275:13484-13492.
33. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
34. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B. 2006. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455-466.
35. Nadler JV. 1981. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 29:2031-2042.
36. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. New York: Academic Press.
37. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A. 1999. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 96:5802-5807.
38. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D. 2006. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21-38.
39. Robinson DA. 1968. The electrical properties of metal electrodes. Proc IEEE 56:1065-1071.
40. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M. 1998. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 51:1256-1262.
41. Stevenson CW, Halliday DM, Marsden CA, Mason R. 2007. Systemic administration of the benzodiazepine receptor partial inverse agonist FG-7142 disrupts corticolimbic network interactions. Synapse 61:646-663.
42. Takahashi KA, Castillo PE. 2006. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 139:795-802.
43. Tropp Sneider J, Chrobak JJ, Quirk MC, Oler JA, Markus EJ. 2006. Differential behavioural state-dependence in the burst properties of CA3 and CA1 neurons. Neuroscience 141:1665-1677.
44. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
45. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM. 1999. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93:969-975.
46. van der Stelt M, Di Marzo V. 2005. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins Other Lipid Mediat 77:111-122.
47. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. 2001. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428:51-57.
48. Wallace MJ, Martin BR, DeLorenzo RJ. 2002. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295-301.
49. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. 2003. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129-137.
50. Westbrook GL, Lothman EW. 1983. Cellular and synaptic basis of kainic acid-induced hippocampal epileptiform activity. Brain Res 273:97-109.
51. Wilson RI, Nicoll RA. 2001. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592.
52. Xi ZX, Gilbert JG, Peng XQ, Pak AC, Li X, Gardner EL. 2006. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: Role of glutamate in the nucleus accumbens. J Neurosci 26:8531-8536.